Biopharma Daily Stock Updates - 07/06/21
$XBI $133.6 -2.2%
COVID Updates
$EIGR +4.2% Eiger BioPharmaceuticals Announces First Patients Dosed with Peginterferon Lambda in Phase 3 TOGETHER Study of Newly Diagnosed COVID-19 Outpatients. source
$DVAX -4.0% Dynavax and Biological E Announce Commercial Supply Agreement of Dynavax's CpG 1018 Adjuvant for Biological E's COVID-19 Vaccine Candidate. source
Pipeline Updates
$NXTC -1.3% NextCure Initiates Phase 1/2 Clinical Trial of NC762 for Solid Tumors. source
$ELOX -0.5% Eloxx Pharmaceuticals Provides Enrollment Update for Ongoing Phase 2 Clinical Studies for Cystic Fibrosis. source
$HCM -11.6% HUTCHMED Initiates Phase I Trials of novel ERK inhibitor HMPL-295 in Patients with Advanced Solid Tumors in China. source
$PRVB -26.4% Provention Bio Receives Complete Response Letter (CRL) to Biologics License Application (BLA) for Teplizumab for the Delay of Clinical Type 1 Diabetes (T1D) in At-risk Individuals. source
$SRNE -2.6% FDA Clears Sorrento Phase 2 Trial Of Non-Opioid Product Candidate Resiniferatoxin (RTX) For Treatment of the Knee Pain in Osteoarthritis (OA) Patients. source
$YMAB -5.6% Y-mAbs Announces NMPA Submission of BLA for DANYELZA® (naxitamab-gqgk) in China. source
$CCXI +6.6% ChemoCentryx Announces Filing of Amendment to NDA Submission and Extension of the PDUFA Review Period for Avacopan in the Treatment of ANCA-Associated Vasculitis. source
$SLNO -3.6% Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome. source
$ASND -1.3% Ascendis Pharma A/S Announces Target Enrollment Achieved in the Phase 3 PaTHway Trial of TransCon™ PTH (palopegteriparatide) in Adults with Hypoparathyroidism (HP) and Provides a Comprehensive Global Clinical Program Update. source
$LGVN -8.3% Longeveron Announces First Patient Treated in Phase 2b Hypoplastic Left Heart Syndrome (HLHS) Clinical Study. source
$SEEL +2.5% Seelos Therapeutics Doses First Patient in Part 2 of a Registrational Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior in Patients with Major Depressive Disorder. source
$ARWR -0.1% Arrowhead Announces Positive Interim Results from Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma. source
$KURA -5.5% Kura Oncology Announces Clinical Collaboration to Evaluate Tipifarnib in Combination with Alpelisib in Head and Neck Squamous Cell Carcinoma. source
$EYPT -5.6% EyePoint Pharmaceuticals Reports Positive 30-day Safety Results for all Cohorts from the DAVIO Trial of EYP-1901 for wet-AMD. source
$MRKR -1.8% Marker Therapeutics Announces Completion of Safety Lead-In Portion of Phase 2 Study in Post-Transplant AML. source
$ATNX -8.1% Athenex Provides Update from FDA Type A Meeting Regarding Oral Paclitaxel Plus Encequidar for the Treatment of Metastatic Breast Cancer. source
$UBX -1.3% UNITY Biotechnology Announces Positive Data from Phase 1 Clinical Trial of UBX1325 in Patients with Advanced Vascular Eye Disease. source
$ATHA +4.4% Athira Pharma Announces Initiation of Open Label Extension Study for LIFT-AD and ACT-AD Clinical Trials of ATH-1017 for Alzheimer’s Disease. source
$TRIL -7.5% Trillium Therapeutics Announces Dosing of First Patient in Phase 1b/2 Study of TTI-622 in Combination With Azacitidine and Venetoclax in TP53-Wild Type Acute Myeloid Leukemia. source
$MNOV -2.9% MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Ophthalmic Disease. source
$ISEE +8.2% Iveric Bio Receives FDA Agreement Under Special Protocol Assessment (SPA) for GATHER2 Phase 3 Clinical Trial of Zimura® in Geographic Atrophy Secondary to Age-Related Macular Degeneration. source
$ALXO +9.7% ALX Oncology Announces New Data from ASPEN-01, the Phase 1b Study of ALX148, Showing Robust Objective Response in Patients with Gastric or Gastroesophageal Junction Cancer. source
Financial Updates
$IDYA +3.0% IDEAYA Announces Proposed Public Offering of Common Stock. source
$TLC +14.7% TLC Announces Details of Stock Swap Transactions. source
$AZN -1.5% AstraZeneca receives clearance from the European Commission for the proposed acquisition of Alexion. source
Posted by FS
Comments